Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.58 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18241886 | 0.77 | GABRA1 (0.38) | GPR3HRH3GABRA1GABRB2BCHE | |
| SCHEMBL8852550 | 0.77 | GPR3 (0.64) | GPR3SLC22A2SLC22A3KMT2AHRH3 | |
| SCHEMBL3485947 | 0.76 | HTR2A (0.42) | GPR3KMT2AGABRA1GABRB2BCHE | |
| SCHEMBL18456626 | 0.76 | GPR3 (0.62) | GPR3SLC22A2SLC22A3KMT2AHRH3 | |
| SCHEMBL6676651 | 0.76 | GPR3 (0.62) | GPR3SLC22A2SLC22A3KMT2AHRH3 | |
| SCHEMBL29151907 | 0.76 | GABRA1 (0.45) | KMT2AGABRA1GABRB2BCHEACHE | |
| SCHEMBL1509312 | 0.75 | GPR3 (1.00) | GPR3SLC22A2SLC22A3KMT2AHRH3 | |
| SCHEMBL28709520 | 0.73 | GPR3 (0.95) | GPR3SLC22A2SLC22A3KMT2AHRH3 | |
| SCHEMBL18456624 | 0.73 | GPR3 (0.58) | GPR3SLC22A2SLC22A3KMT2AHRH3 | |
| SCHEMBL18418388 | 0.73 | GPR3 (0.58) | GPR3SLC22A2SLC22A3KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308607-B2 | Fucosidase inhibitors | HORIZON ORPHAN LLC (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308607-B2 | Fucosidase inhibitors | FUCA1, FUCA2, ENGASE | GPR3 4017/4885SLC22A2 2544/4885SLC22A3 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.